Immune Cell Activity Assay: Principles, Methods, and Applications

Immune cell activity assays are essential laboratory techniques used to evaluate the functional capacity of immune cells, supporting drug development, immunotherapy research, and quality control of biological products. This article provides a comprehensive technical overview of immune cell activity testing, including sample types, testing items, analytical methods, and practical applications. Whether you are researching NK cell cytotoxicity, T cell proliferation, or macrophage phagocytosis, this guide explains how accredited third-party laboratories perform these critical functional assessments.

Technical Overview

Immune cell activity assays encompass a family of in vitro and ex vivo experiments designed to quantify the functional status of immune cells, including their proliferation capacity, cytotoxic potential, cytokine secretion, phagocytic activity, and activation markers. These assays serve as fundamental tools in immunology research, pharmaceutical development, and the biological evaluation of medical devices and biomaterials.

The functional activity of immune cells—rather than their mere presence or count—provides the most meaningful indicator of immunocompetence. Tests such as natural killer (NK) cell cytotoxicity assays, T lymphocyte proliferation assays, and macrophage phagocytosis assays reveal how effectively the immune system can respond to pathogens, tumor cells, or foreign materials. Results from these experiments inform decisions in oncology drug development, vaccine evaluation, immunotoxicity screening, and cell therapy product release.

Proper experimental design requires careful attention to cell isolation purity, viability thresholds (typically above 90–95%), effector-to-target cell ratios, incubation conditions, and appropriate positive and negative controls. Many laboratories align their practices with internationally recognized frameworks such as ISO 10993-20 for immunotoxicity testing of medical devices, ISO 15189 for medical laboratory quality management, and relevant GB/T national standards for laboratory biosafety and cell-based test methods.

Testing Samples

Human Peripheral Blood Samples

Peripheral blood mononuclear cells (PBMCs) isolated from anticoagulated venous blood are the most common sample type for human immune function studies. PBMCs contain lymphocytes (T cells, B cells, NK cells) and monocytes, which can be further purified using density gradient centrifugation or magnetic bead separation. Samples are typically collected in heparinized tubes and processed within a defined time window, usually 24 hours, to preserve cell viability and functional integrity.

Animal Tissue and Blood Samples

In preclinical studies, immune cells are harvested from rodent or other animal models, including spleen, lymph nodes, bone marrow, and peripheral blood. Splenocyte suspensions are frequently used to assess systemic immune function after compound administration or implant material exposure. Animal studies must comply with ethical review requirements and applicable laboratory animal care standards.

Cell Therapy Products

Manufactured immune cell products such as CAR-T cells, CIK cells, NK cell preparations, and tumor-infiltrating lymphocytes (TILs) require functional potency testing before clinical release. Activity assays confirm that the ex vivo expanded cells retain their intended cytotoxic and proliferative capabilities as part of product quality control.

Medical Device Extracts and Biomaterials

According to ISO 10993 series immunotoxicology guidance, extracts from medical devices and biomaterials may be tested for their ability to suppress or stimulate immune cell function. PBMCs or murine splenocytes are exposed to material extracts, and alterations in proliferation, cytokine release, or cytotoxic activity are quantified to identify potential immunomodulatory effects.

Testing Items

Immune cell activity evaluation typically covers the following functional parameters:

• NK cell cytotoxicity against susceptible target cells such as K562 (human) or YAC-1 (murine)
• T lymphocyte proliferation response to mitogens (PHA, ConA) or antigen-specific stimulation
• Cytotoxic T lymphocyte (CTL) target cell killing efficiency
• Macrophage and neutrophil phagocytic activity
• Cytokine secretion profiles, including IFN-γ, IL-2, TNF-α, IL-6, and IL-10
• Cell surface activation markers such as CD69, CD25, and HLA-DR by flow cytometry
• Apoptosis and viability assessment using Annexin V/PI staining
• ADCC (antibody-dependent cellular cytotoxicity) activity of effector cells
• Respiratory burst and reactive oxygen species (ROS) production in phagocytes
• Immunosuppressive or immunostimulatory effects of test compounds, extracts, or biomaterials

Testing Methods

Chromium-51 Release Assay

The classical chromium-51 (51Cr) release assay has long been regarded as the gold standard for measuring cell-mediated cytotoxicity. Target cells are labeled with radioactive 51Cr, co-incubated with effector cells at various effector-to-target ratios, and the radioactivity released into the supernatant upon target cell lysis is measured. Despite its sensitivity, radioactivity handling requirements have driven many laboratories toward non-radioactive alternatives.

LDH Release Assay

The lactate dehydrogenase (LDH) release assay quantifies cytotoxicity by measuring LDH enzyme activity released from damaged target cells into the culture supernatant. This colorimetric or fluorometric method requires no labeling of target cells and is compatible with standard microplate readers, making it convenient for high-throughput screening.

Flow Cytometry-Based Cytotoxicity Assays

Flow cytometric methods label target cells with fluorescent dyes such as CFSE or DiO, while dead or dying cells are detected with propidium iodide or 7-AAD staining. This approach distinguishes effector and target cell populations at the single-cell level, provides higher sensitivity than bulk assays, and reduces assay duration. Multiparametric panels can simultaneously assess degranulation markers such as CD107a and intracellular cytokines.

MTT, CCK-8, and BrdU Proliferation Assays

T cell and lymphocyte proliferation is commonly quantified using metabolic indicators. MTT and CCK-8/WST-1 assays measure the reduction of tetrazolium salts to colored formazan products by metabolically active cells, while BrdU or EdU incorporation reflects DNA synthesis during cell division. Alternatively, CFSE dye dilution analyzed by flow cytometry enables calculation of the proliferation index across successive divisions.

ELISPOT and Intracellular Cytokine Staining

ELISPOT assays detect individual cytokine-secreting cells by capturing secreted molecules on antibody-coated membranes, producing visible spots that are enumerated automatically. Intracellular cytokine staining combined with flow cytometry identifies the phenotype of cytokine-producing cells following brefeldin A-mediated secretion blockade. Both methods are widely used in vaccine immunogenicity studies and T cell response monitoring.

Phagocytosis Assays

Macrophage and neutrophil phagocytic capacity is evaluated using fluorescently labeled target particles, such as pH-sensitive particles, fluorescent bacteria, or opsonized latex beads. Flow cytometry or fluorescence microscopy quantifies the percentage of phagocytosing cells and the mean fluorescence intensity per cell, reflecting both phagocytic frequency and capacity.

Quality Control Considerations

Reliable activity measurements depend on stringent quality controls, including cell viability verification before assay setup, verified effector-to-target ratio titrations, reference control sera or cells, replicate wells with documented coefficient of variation acceptance limits, and calibrated equipment. Accredited third-party laboratories typically operate under ISO 15189-compliant quality systems with method validation covering precision, accuracy, linearity, and robustness.

Applications

Immune cell activity assays support a broad spectrum of research, clinical, and regulatory applications:

• Immunotherapy development, including CAR-T, CAR-NK, TIL, and CIK cell product potency release testing
• Oncology pharmacology studies evaluating immunomodulatory drug candidates and checkpoint inhibitors
• Vaccine efficacy studies measuring antigen-specific T cell responses and cytokine profiles
• Immunotoxicity assessment of medical devices and biomaterials in accordance with ISO 10993-20 principles
• Health product and functional food research examining claimed immunomodulatory benefits
• Drug safety evaluation for compounds with suspected immunosuppressive properties
• Basic immunology research into immune cell differentiation, activation, and exhaustion mechanisms
• Clinical monitoring of immune status in patients undergoing transplantation, chemotherapy, or biological therapy
• Environmental and occupational toxicology studies of immunotoxic exposures

FAQ

What is the difference between immune cell activity and immune cell count?

Cell count and subset distribution (for example, the percentage of CD3+ or CD56+ cells) describe the composition of the immune compartment, whereas activity assays measure functional capability, such as killing efficiency, proliferation rate, or cytokine output. Two samples may show identical cell counts yet differ dramatically in functional activity, which is why functional testing is essential for potency determination.

How are effector-to-target (E:T) ratios selected in cytotoxicity assays?

Typical E:T ratios range from 1:1 to 50:1, and a proper assay includes multiple ratios to generate a dose-response curve. Lower ratios provide better discrimination of high-potency samples, while higher ratios help detect weak activity. The optimal range should be established during method development and validated for linearity within the intended use context.

What sample volume and shipping conditions are required?

Human peripheral blood samples for PBMC isolation generally require 5–20 mL collected in sodium heparin tubes. Samples should be maintained at room temperature (15–25 °C), protected from extreme temperatures, and delivered to the laboratory within 24 hours of collection. Temperature excursions or prolonged transit can significantly impair cell viability and activity, compromising result validity.

Which assay should be chosen for NK cell activity measurement?

Flow cytometry-based cytotoxicity assays are now widely preferred because they avoid radioactivity, offer single-cell resolution, and can be completed within a few hours. The LDH release assay remains a suitable option when flow cytometry is unavailable, while 51Cr release is reserved for laboratories with appropriate radioisotope licensing and historical data comparability requirements.

How long does a typical immune cell activity experiment take?

Turnaround time depends on the assay type. Direct cytotoxicity assays may be completed within one day of cell isolation, whereas proliferation assays require 3–5 days of culture with stimulation, and ELISPOT assays typically involve 24–48 hours of stimulation after cell preparation. Full project timelines, including sample logistics and reporting, generally range from one to three weeks.

Are immune cell activity assays acceptable for regulatory submissions?

Yes. When performed by accredited third-party laboratories under validated methods and documented quality systems aligned with ISO 15189 and relevant ISO 10993 guidance, activity assay data are widely accepted in support of immunotoxicology dossiers, cell therapy investigational applications, and pharmaceutical development records. Study protocols, raw data, and instrument calibration records must be maintained for regulatory review.